

FM/CS/2022/92

March 14, 2022

Ms. Manjula Ramamurthy
Company Secretary & Compliance Officer
Strides Pharma Science Limited
Strides House, Bilekahalli,
Bannerghatta Road, Opposite 11B,
Bengaluru - 560076, Karnataka.

Sub: Reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

We wish to inform you that there has been a change in the shareholding of SBI Mutual Fund under its various schemes, in your company decreasing by 2% from the previous disclosure made by us under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, letter no. FM/CS/2021/395 dated November 30, 2021, wherein the reported holding was 5.4271% of the paid-up share capital of your Company.

SBI Mutual Fund, under its various schemes has sold 1,21,000 shares of your Company, representing 0.1348% of the paid-up share capital of your Company on March 10, 2022.

The final holding of SBI Mutual Fund, under its various schemes, as at the close of business hours on March 10, 2022 was 30,60,598 shares which is 3.4086% of the paid-up share capital of your Company.

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed the required disclosure, as prescribed in the said regulations.

Thanking you,

Yours faithfully,

For SBI Funds Management Limited


Vinaya Datar
Chief Compliance Officer & Company Secretary

Encl: As above

- c.c. 1. National Stock Exchange of India Limited
Listing Department
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051.
2. General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Trustee: **SBI Mutual Fund Trustee Company Private Limited** (CIN: U65991MH2003PTC138496)


9th Floor, Crescenzo, Plot C-38 & 39, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.
Tel.: +91 22 61793000 | Fax: +91 22 67425687-91 | Website: www.sbimf.com

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	STRIDES PHARMA SCIENCE LIMITED		
2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	SBI Mutual Fund under its various schemes		
3. Whether the acquirer belongs to Promoter/Promoter group	N.A.		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Ltd / National Stock Exchange of India Ltd		
5. Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC(**)
Before the acquisition/disposal under consideration, holding of:			
a) Shares carrying voting rights	3,181,598	3.5434%	N.A.
b) Share in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N.A.	N.A.	N.A.
c) Voting rights (VR) otherwise than by shares	N.A.	N.A.	N.A.
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	N.A.	N.A.	N.A.
Total (a+b+c+d)	3,181,598	3.5434%	N.A.
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	121,000	0.1348%	N.A.
b) VRs acquired /sold otherwise than by shares	N.A.	N.A.	N.A.
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	N.A.	N.A.	N.A.
d) Shares encumbered/ invoked/ released by the acquirer	N.A.	N.A.	N.A.
Total (a+b+c+d)	121,000	0.1348%	N.A.
After the acquisition/sale, holding of:			
a) Shares carrying voting rights	3,060,598	3.4086%	N.A.
b) Shares encumbered with the acquirer	N.A.	N.A.	N.A.
c) VRs otherwise than by shares	N.A.	N.A.	N.A.
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition.	N.A.	N.A.	N.A.
Total (a+b+c+d)	3,060,598	3.4086%	N.A.
6. Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Market Sale		
7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Sold 121,000 shares on 10-March-2022		
8. Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 8,97,90,2140/- consisting of 8,97,90,214 equity shares having a face value of Rs. 10/- each.		
9. Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 8,97,90,2140/- consisting of 8,97,90,214 equity shares having a face value of Rs. 10/- each.		
10. Total diluted share/voting capital of the TC after the said acquisition/sale.	N.A.		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

 For

 Ravindra Kash Sharma
 Dealer
 Signature of the acquirer/ seller/ Authorised Signatory
 Place: Mumbai
 Date: 11-March-2022


 Aparna Nirgude
 Chief Risk Officer